Ibrutinib treatment improves T cell number and function in CLL patients

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS. Peripheral...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Invest
Главные авторы: Long, Meixiao, Beckwith, Kyle, Do, Priscilla, Mundy, Bethany L., Gordon, Amber, Lehman, Amy M., Maddocks, Kami J., Cheney, Carolyn, Jones, Jeffrey A., Flynn, Joseph M., Andritsos, Leslie A., Awan, Farrukh, Fraietta, Joseph A., June, Carl H., Maus, Marcela V., Woyach, Jennifer A., Caligiuri, Michael A., Johnson, Amy J., Muthusamy, Natarajan, Byrd, John C.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2017
Предметы:
Clinical Medicine
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5531425/
https://ncbi.nlm.nih.gov/pubmed/28714866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89756
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы